Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714540 | 0.82 | PSEN1 (0.37) | ALDH1A1MEN1POLBKMT2ACPB1 | |
| SCHEMBL6710676 | 0.78 | SCN9A (0.45) | GAAMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL7499041 | 0.78 | OPRM1 (0.45) | CCR5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL7529516 | 0.77 | HTR6 (0.45) | HTR6GAAALDH1A1MEN1MAPK1 | |
| SCHEMBL7533916 | 0.74 | HTR6 (0.38) | HTR6ALDH1A1POLBKMT2AHPGD | |
| SCHEMBL7492223 | 0.72 | HTT (0.39) | MEN1TSHRKMT2APKMSMN1; SMN2 | |
| SCHEMBL6290202 | 0.72 | HTR6 (0.42) | HTR6ALDH1A1MEN1POLBTSHR | |
| SCHEMBL7498243 | 0.71 | OPRD1 (0.44) | KMT2A | |
| SCHEMBL7497373 | 0.71 | SLC6A2 (0.41) | KMT2AHPGD | |
| SCHEMBL5871033 | 0.71 | OPRD1 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872716-B2 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | WU XINHE (US) | 2004-11-25 | — | — | US | disclosed |
| US-6703383-B2 | HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002022579-A2 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | TRPV1, CNR2, TRPM5 | HTR6 231/4885CCR5 2297/4885GAA 3079/4885 |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | TRPV1, CNR2, TRPM5 | HTR6 231/4885CCR5 2297/4885GAA 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.